An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
American Society of Hematology to recognize Dr. Oliver Press for outstanding mentorship
Aug. 24, 2017
The American Society of Hematology, or ASH, announced that Fred Hutch’s Dr. Oliver “Ollie” Press, an internationally known expert in lymphoma and other blood cancers, will receive an award for outstanding mentorship Dec. 10 at the 59th ASH Annual Meeting and Exposition in Atlanta.
Fred Hutchinson Cancer Research Center bioengineer and cancer researcher Dr. Cyrus Ghajar has focused much of his work on what causes breast cancer cells to metastasize. Now, with the help of a new $1 million grant from the W.M. Keck Foundation, Ghajar and his team are hoping to crack open a mystery that has long puzzled scientists in the field: Why do metastatic cells, which can proliferate in many organs, nearly always fail to grow in skeletal muscles, which account for as much as half the body mass of an adult?
The impact of Dr. Oliver Press, pioneering researcher, beloved physician and influential mentor
May 1, 2017
| by Susan Keown / Fred Hutch News Service
Once a boy with an obsession for animals, he's now a doctor and researcher known around the world for his dedication to saving patients' lives. (And he's still obsessed with animals.) Meet Dr. Oliver Press.
Dr. Glenda Gray among Time magazine’s ‘100 most influential’; Fred Hutch license plates coming soon; UW establishes Dr. Oliver W. Press Distinguished MSTP Alumnus Award; and Dr. Vivian Oehler receives ASH Bridge Grant for leukemia research.